Blog
How can real-world data support opioid addiction research? Q&A with Dr. Jacob “Gus” Crothers of Groups Recover Together
The opioid epidemic is one of the greatest public health challenges this century, and its ...
Blog
ICPE research spotlight: Part III: Standard-setting research to advance the use of RWE
This year at ICPE All Access, Aetion’s scientific research is represented across 15 ...
Blog
Generating real-world evidence from chargemaster data: Q&A with Myla Maloney of Premier, Inc.
Most real-world data (RWD) sets are based on claims data, which provides useful ...
Blog
Can synthetic data help organizations respond to 'Schrems II'?
By Mike Hintze, Khaled El Emam Posted On: October 28th, 2020 Can synthetic data help ...
Blog
How can small- to mid-sized biopharma generate insights from RWD? Q&A with Michael Sanky of Optum Life Sciences
Optum, a new Aetion data collaborator, offers a robust range of real-world data (RWD) ...
Blog
Unlocking insights in RWD for market access and commercial teams: Q&A with Ki Park of Symphony Health
The integrated solutions of Symphony Health, a new Aetion data partner, extract data from ...
Blog
ICPE research spotlight: Part II: Exploring new methods for RWE research
This year at ICPE All Access, Aetion’s scientific research is represented across 15 ...
Blog
Ask the Accelerators: Dr. William Morice of Mayo Clinic Laboratories on RWE and COVID-19 diagnostics
Ask the Accelerators is a series highlighting the perspectives and work of organizations ...
Blog
PETs and Sharing Clinical Trial Data
Janssen’s Head of Clinical Data Standards & Transparency, Stephen Bamford, recently ...
Blog
ICPE research spotlight: Part I: Expanding real-world applications of RWE
This year at ICPE All Access, Aetion’s scientific research is represented across 15 ...
Blog
Ask the Accelerators: Dr. Nirosha Lederer on COVID-19’s implications for the future of RWE, and what we’ve learned so far
Ask the Accelerators is a series highlighting the perspectives and work of organizations ...
Blog
Three recommendations for generating regulatory-grade RWE: Considerations for the FDA on PDUFA VII
With the passage of the 21st Century Cures Act and the sixth Prescription Drug User Fee ...
Blog
Structuring epidemiology teams to maximize impact of RWE: Q&A with Dr. Nicolle Gatto
Nicolle Gatto, Ph.D., is the Senior Vice President of Scientific Research at Aetion, ...
Blog
Death to Privacy Shield
PETs to the Rescue in the Wake of the Privacy Shield Verdict Due to contemporary ...
Blog
How can AI and RWD work together to improve understanding of chronic diseases? Q&A with Kathryn Starzyk, Head of RWE at OM1
OM1, a new Aetion data partner, curates deep clinical real-world data (RWD) from ...
Blog
PETs to Manage Emerging Privacy Risks
As the pace of technological innovation continues to grow, new risks to consumer and ...
Blog
Real-world evidence and regulatory decision-making: A round-up of readings on progress to date, and what’s to come
In recent years, the U.S. Food and Drug Administration (FDA) and other global regulatory ...
Blog
Lessons from four recent FDA decisions in infectious disease
The use of real-world evidence (RWE) has proven pivotal to research in infectious ...
Blog
The Cures Act’s second act: Six ways to ensure Congress doubles down on its boldest bet
In the article below, originally published in Morning Consult, Carolyn Magill, CEO of ...
Blog
How to generate insights on COVID-19 interventions with real-world data: Three learnings from the COVID-19 Therapeutics Evidence Accelerator
The COVID-19 Evidence Accelerator, organized by the Reagan-Udall Foundation for the FDA ...
Blog
What’s ahead for the use of RWE by regulators and HTAs? Q&A with Dr. Lucinda Orsini, Associate Chief Science Officer of ISPOR
Lucinda Orsini, D.P.M., M.P.H., has decades of experience working with biopharma, ...
Blog
Financing innovative therapies in the era of COVID-19: The collaborative work ahead
Much discussion surrounds how our society will pay for curative and high cost therapies, ...
Blog
The case for regulator-HTA collaboration on RWE methodology standards
Regulatory and health technology assessment (HTA) bodies have announced their commitment ...
Blog
Trends and predictions for RWE: Perspectives from Dr. Sean Hennessy, pharmacist and pharmacoepidemiologist
Sean Hennessy, Pharm.D., Ph.D., is a pharmacist and pharmacoepidemiologist who feels he ...